PMID: 21332310

Lemos C, Giovannetti E, Zucali PA, Assaraf YG, Scheffer GL, van der Straaten T, D'Incecco A, Falcone A, Guchelaar HJ, Danesi R, Santoro A, Giaccone G, Tibaldi C, Peters GJ
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.
Pharmacogenomics. 2011 Feb;12(2):159-70., [PubMed]
Sentences
No. Mutations Sentence Comment
7 ABCG2 p.Gln141Lys
X
ABCG2 p.Gln141Lys 21332310:7:70
status: NEW
view ABCG2 p.Gln141Lys details
ABCG2 p.Gln141Lys
X
ABCG2 p.Gln141Lys 21332310:7:131
status: NEW
view ABCG2 p.Gln141Lys details
 In particular, the nonsynonymous SNP ABCG2 421C/A, which results in a glutamine to lysine amino acid substitution at position 141 (Q141K), has been associated with markedly decreased levels of ABCG2 protein expression [11-13] and/or activity [14-16]. Login to comment 236 ABCG2 p.Gln141Lys
X
ABCG2 p.Gln141Lys 21332310:236:144
status: NEW
view ABCG2 p.Gln141Lys details
 11 Imai Y, Nakane M, Kage K et al.: C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther. 1, 611-616 (2002). Login to comment